Coherus Biosciences (NASDAQ:CHRS) released its quarterly earnings data on Thursday. The biotechnology company reported ($0.87) EPS for the quarter, missing analysts’ consensus estimates of ($0.79) by ($0.08), Morningstar.com reports.

NASDAQ:CHRS traded down $1.88 on Friday, reaching $10.06. The company’s stock had a trading volume of 2,369,603 shares, compared to its average volume of 892,346. Coherus Biosciences has a 1-year low of $8.05 and a 1-year high of $20.66. The company has a current ratio of 7.79, a quick ratio of 7.79 and a debt-to-equity ratio of 1.66. The stock has a market cap of $846.40 million, a price-to-earnings ratio of -2.24 and a beta of 3.72.

In other news, Director James Healy sold 25,000 shares of the company’s stock in a transaction dated Wednesday, August 29th. The stock was sold at an average price of $20.50, for a total transaction of $512,500.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, insider Barbara K. Finck sold 1,760 shares of the company’s stock in a transaction dated Monday, September 10th. The stock was sold at an average price of $18.58, for a total value of $32,700.80. Following the transaction, the insider now directly owns 38,803 shares of the company’s stock, valued at $720,959.74. The disclosure for this sale can be found here. Over the last three months, insiders sold 28,520 shares of company stock valued at $578,676. Insiders own 26.28% of the company’s stock.

Hedge funds have recently bought and sold shares of the company. Tower Research Capital LLC TRC acquired a new position in shares of Coherus Biosciences during the second quarter worth about $118,000. Hartwell J M Limited Partnership acquired a new position in shares of Coherus Biosciences during the second quarter worth about $140,000. Principal Financial Group Inc. acquired a new position in shares of Coherus Biosciences during the first quarter worth about $115,000. Dynamic Technology Lab Private Ltd acquired a new position in shares of Coherus Biosciences during the second quarter worth about $193,000. Finally, BlueMountain Capital Management LLC acquired a new position in shares of Coherus Biosciences during the second quarter worth about $214,000. 91.25% of the stock is owned by institutional investors.

A number of equities research analysts recently commented on the company. BidaskClub downgraded Coherus Biosciences from a “buy” rating to a “hold” rating in a report on Tuesday, September 11th. ValuEngine downgraded Coherus Biosciences from a “strong-buy” rating to a “buy” rating in a report on Friday, September 14th. Zacks Investment Research upgraded Coherus Biosciences from a “sell” rating to a “hold” rating in a report on Tuesday, October 9th. HC Wainwright set a $28.00 price objective on Coherus Biosciences and gave the company a “buy” rating in a report on Monday, November 5th. Finally, Cowen reiterated a “buy” rating and issued a $45.00 price objective on shares of Coherus Biosciences in a report on Friday, November 2nd. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and five have issued a buy rating to the company’s stock. Coherus Biosciences has an average rating of “Buy” and a consensus target price of $27.20.

WARNING: This report was originally posted by Daily Political and is the sole property of of Daily Political. If you are accessing this report on another site, it was illegally copied and reposted in violation of US and international trademark and copyright law. The correct version of this report can be viewed at https://www.dailypolitical.com/2018/11/10/coherus-biosciences-chrs-issues-earnings-results-misses-expectations-by-0-08-eps.html.

About Coherus Biosciences

Coherus BioSciences, Inc, a biosimilar company, develops and commercializes various therapeutic products worldwide. The company engages in the development of late-stage clinical products, including CHS-1701 pegfilgrastim biosimilar, a granulocyte colony-stimulating factor product candidate; CHS-1420 adalimumab biosimilar, an anti-tumor necrosis factor product candidate; and CHS-0214, an etanercept biosimilar for rheumatoid arthritis and psoriasis.

Featured Story: Bull Market

Earnings History for Coherus Biosciences (NASDAQ:CHRS)

Receive News & Ratings for Coherus Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coherus Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.